Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven W Lane

Showing results (1-10 of 107) with videos related to

Pageof 11
Sort By:
Blood|November 15, 2019
Inflammation in del(20q): a MST opportunity?Steven W Lane
Blood|January 17, 2012
Bad to the boneSteven W Lane
Blood|May 18, 2023
Shelter from the cytokine storm in myelofibrosisSteven W Lane
Nature Communications|August 26, 2022
Paving the way to improve therapy for Myeloproliferative NeoplasmsMegan Bywater, Steven W Lane
Blood|February 26, 2026
CD38+ monocytes fuel fibrosis in myeloproliferative neoplasmAlban Johansson, Steven W Lane
Haematologica|March 16, 2023
The TRIM31 paradox: an unexpected benefit for leukemia stem cellsJasmin Straube, Steven W Lane
Oncotarget|May 11, 2013
Jak2V617F myeloproliferative neoplasm stem cells and interferon-alphaSteven W Lane, Ann Mullaly
Blood Advances|April 23, 2024
Survival for the fittest: guadecitabine in rel/ref AMLJoshua Sheehy, Steven W Lane
Current Opinion in Hematology|May 24, 2016
Telomerase in hematologic malignanciesClaudia Bruedigam, Steven W Lane
Blood|November 13, 2025
Decoding RNA modifications to unlock new treatments for AMLSteven W Lane, Megan Bywater
Pageof 11

Showing results (1-10 of 107) with videos related to

Sort By:
Pageof 11
Blood|November 15, 2019
Inflammation in del(20q): a MST opportunity?Steven W Lane
Blood|January 17, 2012
Bad to the boneSteven W Lane
Blood|May 18, 2023
Shelter from the cytokine storm in myelofibrosisSteven W Lane
Nature Communications|August 26, 2022
Paving the way to improve therapy for Myeloproliferative NeoplasmsMegan Bywater, Steven W Lane
Blood|February 26, 2026
CD38+ monocytes fuel fibrosis in myeloproliferative neoplasmAlban Johansson, Steven W Lane
Haematologica|March 16, 2023
The TRIM31 paradox: an unexpected benefit for leukemia stem cellsJasmin Straube, Steven W Lane
Oncotarget|May 11, 2013
Jak2V617F myeloproliferative neoplasm stem cells and interferon-alphaSteven W Lane, Ann Mullaly
Blood Advances|April 23, 2024
Survival for the fittest: guadecitabine in rel/ref AMLJoshua Sheehy, Steven W Lane
Current Opinion in Hematology|May 24, 2016
Telomerase in hematologic malignanciesClaudia Bruedigam, Steven W Lane
Blood|November 13, 2025
Decoding RNA modifications to unlock new treatments for AMLSteven W Lane, Megan Bywater
Pageof 11